



Kilitch Drugs (India) Ltd.

Admin. Off. : 37, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088.
• Tel. : +91-22-6121 4100 • Fax : +91-22-6703 1658
Regd. Off. : C-301/2, M.I.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705, Maharashtra
& Factory • Tel. : +91-22-6514 4185 / 2768 0913 • Fax : +91-22-2768 0912
• E-mail : info@kilitch.com • Website : www.kilitch.com

August 14, 2013

To,
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051.

Respected Sir,

Scrip ID: KILITCH

Sub: Limited Review Report for the quarter ended June 30, 2013.

With reference to the captioned subject, we are enclosing herewith Limited Review Report for the quarter ended June 30, 2013 as received from the Statutory Auditors of the Company, M/s. RNR Iyer & Co, Chartered Accountants, Mumbai.

Kindly find the same in order and acknowledge the same.

Thanking You,

Yours faithfully,

For KILITCH DRUGS (INDIA) LIMITED



MUKUND P. MEHTA
MANAGING DIRECTOR

Encl.a/a.




M/S R N R IYER & CO., Chartered Accountants.**No 10 Vaishak, 2B P.K.Road, Nahur, Mulund west, Mumbai -400080.****Tel: 022-25643138, E-mail: rnriyerca@fastmail.fm****Limited Review Report to the Board of Directors of Mis**
Kilitch Drugs India Limited

We have reviewed the accompanying statement of un-audited financial results of M/s. Kilitch Drugs India Limited for the quarter ended 30th June, 2013, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity issued by the Institute of the Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and, thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements prepared in accordance with the Accounting Standards referred to in Section 211 (3C) of the Companies Act, 1956 and other recognized accounting practices and policies has not disclosed the information required in terms of Clause 41 of the Listing Agreements with Stock Exchanges including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s R N R Iyer & Co.,
Chartered Accountants

FRN 103768W

Iyer Rajkumar
(Proprietor)

Mem. No. 033964**Mumbai****Dated: 14th August, 2013**

KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2013

Rs. In lacs

PART I	Particulars	3 MONTHS ENDED	3 MONTHS ENDED	3 MONTHS ENDED	TWELVE MONTHS
		30th JUNE 2013	30th JUNE 2012	31ST MARCH 2013	ENDED
					31ST MARCH 2013
		UNAUDITED	UNAUDITED	AUDITED	AUDITED
1	Income from operations				3199.01
	(a) Net Sales/Income from operations (net of Excise)	368.66	1481.43	783.26	119.07
	(b) Other operating income	0.00	0.00	119.07	3318.08
	Total income from Operations (Net)	368.66	1481.43	902.33	2659.83
2	Expenses	237.67	1391.44	704.34	
	(a) Cost of materials consumed				
	(b) Purchased of Stock-in-trade				
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(44.04)	(119.54)	1.68	26.13
	(d) Employee benefit expenses	60.80	59.23	77.30	303.45
	(e) Depreciation and amortisation expenses	33.08	32.81	24.45	122.90
	(f) Other expenses (Any item exceeding 10% of the expenses relating to continuing operations to be shown separately)	109.52	142.37	187.30	695.89
	Total Expenses	397.02	1506.31	995.07	3808.20
	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(28.37)	(24.88)	(92.74)	(490.12)
3	Other Income (Dividend from mutual funds and other income)	210.52	329.67	123.45	915.05
4	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	182.15	304.79	30.71	424.93
5	Finance Costs	6.18	2.97	(5.25)	1.91
6	Profit / (Loss) from ordinary activities after finance cost but before exceptional items (5-6)	175.97	301.82	35.97	423.02
7	Exceptional items	0.00	0.00	0.00	0.00
8	Profit / (Loss) from ordinary activities before tax (7+8)	175.97	301.82	35.97	423.02
9	Tax Expenses	0.00		(2.71)	(0.71)
10	Net Profit / (Loss) from ordinary activities after tax (9-10)	175.97	301.82	38.68	423.73
11	Extra Ordinary Items (net of tax expenses Rs. Lakhs)	0.00	0.00	95.46	95.46
12	Net Profit / (Loss) for the period (11+12)	175.97	301.82	(56.78)	328.27
13	Share of Profit / (Loss) of associates	0.00	0.00	0.00	0.00
14	Minority interest	0.00	0.00	0.00	0.00
15	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	175.97	301.82	(56.78)	328.27
16	Paid-Up equity share capital	1323.18	1323.18	1323.18	1323.18
17	(Face Value of the Share shall be indicated Rs. 10/-)				
18	Reserve excluding Revaluation Reserve as per Balance sheet of previous accounting year				10582.00
19.i	Earnings per share (before extra ordinary items) (In Rs.)				
	(of Rs. 10 /-each) (not annualised):				
	(a) Basic	1.33	2.28	0.29	3.20
	(b) Diluted	1.31	2.08	0.29	3.15
19.ii	Earnings per share (after extra ordinary items) (In Rs.)				
	(of Rs. 10 /-each) (not annualised):				
	(a) Basic	1.33	2.28	(0.43)	2.48
	(b) Diluted	1.31	2.08	(0.42)	2.44
	See accompanying note to the financial results				



KILITCH DRUGS (INDIA) LIMITED

PART II

Particulars	3 MONTHS ENDED	3 MONTHS ENDED	3 MONTHS ENDED	YEAR TO DATE
	30th JUNE 2013	30th JUNE 2012	31ST MARCH 2013	ENDED 31ST MARCH 2013
	UNAUDITED	UNAUDITED	AUDITED	AUDITED
A SHAREHOLDING				
1 Public shareholding				
Number of shares	4706393	4706393	4706393	4706393
Percentage of shareholding	35.57	35.57	35.57	35.57
2 Promoters and Promoter Group Shareholding				
a) Pledge / Encumbered				
Number of shares	NIL	NIL	NIL	NIL
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL
Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL
b) Non- encumbered				
Number of shares	8525435	8525435	8525435	8525435
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
Percentage of shares (as a % of the total share capital of the company)	64.43	64.43	64.43	64.43

Particulars	3 months ended 30th June 2013
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	13
Disposed or during the quarter	13
Remaining unresolved at the end of the quarter	NIL

- The above results were reviewed by the Audit Committee and thereafter taken on record and approved by the Board of Directors at their meeting held on 14th August 2013. The Statutory Auditors have conducted a limited review of these financial results.
- The Company has only one primary reportable segment-Pharmaceuticals.
- The previous years/period figures have been regrouped and reclassified wherever required to conform with current year/period figures.

Place :
Date:

Mumbai
14th August 2013



By and on Behalf of the Board
for Kilitch Drugs (India) Ltd.
Mukund P Mehta
Mukund P Mehta
Managing Director